EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 June 2022
EMA/CHMP/576014/2022
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Lonquex

lipegfilgrastim

On 23 June 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lonquex. The marketing authorisation holder for this medicinal product is Teva B.V.

The CHMP adopted an extension to an existing indication to include use in children 2 years of age and older.

For information, the full indication for Lonquex will therefore be as follows:[2]

> Lonquex is indicated in adults **and in children 2 years of age and older** for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in **bold**

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union